ATE325865T1 - Isolierung von sezernierte proteine exprimierenden zellen - Google Patents

Isolierung von sezernierte proteine exprimierenden zellen

Info

Publication number
ATE325865T1
ATE325865T1 AT02713420T AT02713420T ATE325865T1 AT E325865 T1 ATE325865 T1 AT E325865T1 AT 02713420 T AT02713420 T AT 02713420T AT 02713420 T AT02713420 T AT 02713420T AT E325865 T1 ATE325865 T1 AT E325865T1
Authority
AT
Austria
Prior art keywords
poi
isolation
cells expressing
secreted proteins
cell
Prior art date
Application number
AT02713420T
Other languages
English (en)
Inventor
James P Fandl
Neil Stahl
Gang Chen
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE325865T1 publication Critical patent/ATE325865T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02713420T 2001-01-16 2002-01-16 Isolierung von sezernierte proteine exprimierenden zellen ATE325865T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26199901P 2001-01-16 2001-01-16

Publications (1)

Publication Number Publication Date
ATE325865T1 true ATE325865T1 (de) 2006-06-15

Family

ID=22995765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713420T ATE325865T1 (de) 2001-01-16 2002-01-16 Isolierung von sezernierte proteine exprimierenden zellen

Country Status (10)

Country Link
US (3) US6919183B2 (de)
EP (1) EP1392859B1 (de)
JP (1) JP4323167B2 (de)
AT (1) ATE325865T1 (de)
AU (1) AU2002245272B2 (de)
CA (1) CA2434802C (de)
DE (1) DE60211329T2 (de)
HK (1) HK1059290A1 (de)
IL (2) IL156910A0 (de)
WO (1) WO2002057423A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434802C (en) * 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) * 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
NZ537221A (en) * 2002-05-22 2007-03-30 Biogen Idec Inc Detection of a secreted polypeptide on the surface of a cell used as a marker for cellular productivity of the secreted polypeptide
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2005019823A1 (en) * 2003-08-20 2005-03-03 Celltech R & D Limited Methods for obtaining antibodies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
EP2420832A1 (de) 2006-05-04 2012-02-22 Abmaxis, Inc. Artenübergreifende und Mehrartenanzeigesysteme
JP4870208B2 (ja) 2006-05-17 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
BRPI0807952A2 (pt) * 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
EP2137308B1 (de) 2007-03-26 2016-08-03 Agenus Inc. Zelloberflächenpräsentation, screening und produktion von interessierenden proteinen
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
CA2710122A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
WO2009103753A1 (en) * 2008-02-20 2009-08-27 Ablynx Nv Methods for identifying and/or sorting cells by secreted molecule and kits for performing such methods
EP2263089B1 (de) 2008-03-03 2015-01-28 GlycoFi, Inc. Oberflächenanzeige rekombinanter proteine bei niederen eukaryoten
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
KR101498668B1 (ko) 2008-12-04 2015-03-06 한국생명공학연구원 고분비성 단백질의 스크리닝 및 재조합 단백질의 생산을 위한 융합 파트너로서 그의 용도
PL2438171T3 (pl) 2009-06-02 2015-04-30 Regeneron Pharma Komórki z niedoborem fukozylacji
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8278873B2 (en) * 2009-09-10 2012-10-02 Syntheon, Llc Surgical sterilizer with integrated battery charging device
CA2789446A1 (en) * 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP2390661B1 (de) * 2010-05-02 2015-06-24 Miltenyi Biotec GmbH Verankerungs-/Erfassungsmittel zum Auswählen oder Analysieren einer CHO-Zelle entsprechend einem Produkt, das von der CHO-Zelle sezerniert wird
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012060666A2 (ko) 2010-11-04 2012-05-10 한국생명공학연구원 효모에서 인체 상피세포 성장인자를 대량 생산하는 방법
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
ES2611885T3 (es) 2011-01-31 2017-05-11 Novartis Ag Derivados heterocíclicos novedosos
CN102680679B (zh) * 2011-03-15 2014-08-27 中国科学院上海生命科学研究院 检测单细胞特异性抗体分泌的细胞微孔芯片及其制备方法
PL2771342T3 (pl) 2011-10-28 2016-11-30 Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
US9890378B2 (en) 2012-05-11 2018-02-13 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
SG10201608469RA (en) 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2888283B1 (de) 2012-08-24 2018-09-19 The Regents of The University of California Antikörper und impfstoffe zur verwendung bei der behandlung von ror1-krebsarten und zur metastasenhemmung
TWI675044B (zh) * 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9353163B2 (en) 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
HUE039551T2 (hu) 2013-10-11 2019-01-28 Regeneron Pharma Metabolikusan optimalizált sejttenyészet
CN105979947A (zh) 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3370719A1 (de) 2015-11-02 2018-09-12 Novartis AG Dosierungsplan für einen phosphatidylinositol-3-kinase-inhibitor
WO2017132701A1 (en) * 2016-01-31 2017-08-03 Shuang Zhang Method for screening antibodies
WO2017136734A1 (en) * 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
EP3464332A1 (de) 2016-05-26 2019-04-10 University College Cork - National University of Ireland, Cork Verfahren zur erhöhung der proliferation von säugetierzellen
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
WO2018041740A1 (en) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Non-covalent display system using fimgt/dsf
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018060239A1 (en) 2016-09-29 2018-04-05 F. Hoffmann-La Roche Ag Improved method for selecting polypeptide producing cells
GB201703418D0 (en) 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
GB201704115D0 (en) * 2017-03-15 2017-04-26 Oxford Genetics Ltd Method of selecting for antibodies
EP3601558A4 (de) * 2017-03-24 2021-01-06 Lankenau Institute for Medical Research Verfahren und zusammensetzungen zur induzierbaren extrazellulären membranaufnahme von monoklonalen immunglobulinen, die von hybridomen abgesondert werden
US11833178B2 (en) 2017-08-25 2023-12-05 University College Cork—National University of Ireland, Cork Bifidobacterium longum for treating obesity and weight management
WO2019102018A2 (en) 2017-11-24 2019-05-31 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
EP3604507A1 (de) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork Omega-transaminase-enzym
EP3853367A4 (de) * 2018-09-17 2022-06-22 South Australian Health and Medical Research Institute Limited Verfahren zur herstellung von proteinen
US20200318136A1 (en) * 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
AU2020334196A1 (en) 2019-08-20 2022-03-03 Nuritas Limited Peptides for treating muscle atrophy
EP3783012A1 (de) 2019-08-20 2021-02-24 Nuritas Limited Antimikrobielles peptid
BR112022007047A2 (pt) 2019-10-22 2022-07-05 Nuritas Ltd Tratamento de doença hepática gordurosa não alcoólica
JPWO2022190733A1 (de) * 2021-03-10 2022-09-15
EP4070670A1 (de) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 und verwendungen davon
AU2022259536A1 (en) 2021-04-14 2023-11-09 University College Cork - National University Of Ireland, Cork Treatment of cerebrovascular events and neurological disorders
CA3214579A1 (en) 2021-04-14 2022-10-20 Tom Moore Psg1 for use in the treatment of osteoarthritis
AU2022360838A1 (en) 2021-10-07 2024-03-28 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CA3230985A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Ph meter calibration and correction
US20230287043A1 (en) 2022-03-02 2023-09-14 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury
CN118006552A (zh) * 2024-04-09 2024-05-10 暨南大学 一种抗原特异性浆细胞的筛选方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2191677T3 (es) * 1992-10-21 2003-09-16 Stefan Miltenyi Seleccion directa de celulas mediante un producto de secrecion.
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
CA2330678C (en) 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
CA2434802C (en) * 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins

Also Published As

Publication number Publication date
EP1392859A4 (de) 2004-11-24
WO2002057423A3 (en) 2003-12-18
US20050186623A1 (en) 2005-08-25
WO2002057423A2 (en) 2002-07-25
EP1392859A2 (de) 2004-03-03
US20060234311A1 (en) 2006-10-19
IL156910A (en) 2009-08-03
HK1059290A1 (en) 2004-06-25
EP1392859B1 (de) 2006-05-10
US7435553B2 (en) 2008-10-14
JP4323167B2 (ja) 2009-09-02
CA2434802A1 (en) 2002-07-25
JP2004520037A (ja) 2004-07-08
US20020168702A1 (en) 2002-11-14
IL156910A0 (en) 2004-02-08
DE60211329T2 (de) 2007-05-24
DE60211329D1 (de) 2006-06-14
AU2002245272B2 (en) 2006-06-29
US6919183B2 (en) 2005-07-19
CA2434802C (en) 2013-05-28

Similar Documents

Publication Publication Date Title
ATE325865T1 (de) Isolierung von sezernierte proteine exprimierenden zellen
CN107525842B (zh) 一种用于研究蛋白质结构或蛋白质相互作用的分析方法
Palandra et al. Highly specific and sensitive measurements of human and monkey interleukin 21 using sequential protein and tryptic peptide immunoaffinity LC-MS/MS
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
Ackermann et al. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers
WO2003068947A8 (en) Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
WO2002079490A3 (en) Bio-barcodes based on oligonucleotide-modified particles
WO2000054046A3 (en) Universal protein array system
Chojnacki et al. Polyubiquitin-photoactivatable crosslinking reagents for mapping ubiquitin interactome identify Rpn1 as a proteasome ubiquitin-associating subunit
EP3044322A1 (de) Bimolekularer proteasebasierter biosensor
EP1499885A4 (de) Neue fusionsproteine und molekulare bindungsassays
WO2006107813A3 (en) Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-trna synthetase
IS2163B (is) Vatnsfælanlega-umbreyttar prótín samsetningar og aðferðir
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
Swaney et al. Proteomic analysis of protein posttranslational modifications by mass spectrometry
WO2006004936A3 (en) Analysis of intracellular modifications
WO2003016904A3 (en) Peptide sequence tags and method of using same
WO2002064747A3 (en) Fusion proteins based upon somatostatin receptors
DE50107766D1 (de) Zweifarbiges fluorimetrisches proteaseassay
WO2003020005A3 (en) Lp mammalian proteins; related reagents
WO2003062444A3 (en) Array systems and methods
HUP0101987A2 (hu) Antibiotikus hatású proteinek és peptidek indukciója LAIT/sCD14-proteinnel
ATE348190T1 (de) Verfahren zum nachweis von protein- proteininteraktionen in membranen
WO2005047305A3 (en) Cellular membrane protein assay

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392859

Country of ref document: EP